Pharmacokinetic profile of a 24-hour controlled-release OROS® formulation of hydromorphone in the presence and absence of food

BMC Clinical Pharmacology

Volumn 7, Issue , 2007, Pages

  Sathyan, Gayatri ^a   Xu, Emily ^a   Thipphawong, John ^a   Gupta, Suneel K ^a  

^a ALZA CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROMORPHONE; NALTREXONE; OROS; UNCLASSIFIED DRUG; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ABNORMAL LABORATORY RESULT; ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BIOEQUIVALENCE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; LIPID DIET; MALE; MONOTHERAPY; NAUSEA; NORMAL HUMAN; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; VOMITING; BIOAVAILABILITY; BLOOD; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; HALF LIFE TIME; MIDDLE AGED;

ADULT; ANALGESICS, OPIOID; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; FEMALE; FOOD-DRUG INTERACTIONS; HALF-LIFE; HUMANS; HYDROMORPHONE; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS;

EID: 33847769847     PISSN: None     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-7-2     Document Type: Article

References (15)

1. Quigley C Wiffen P A systematic review of hydromorphone in acute and chronic pain J Pain Symptom Manage 2003 25 169-178 10.1016/ S0885-3924(02)00643-7 12590032
2. Hill HF Coda BA Tanaka A Schaffer R Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects Anesth Analg 1991 72 330-336 10.1213/00000539-199103000-00009 1704690
3. Vallner JJ Stewart JT Kotzan JA Kirsten EB Honigberg IL Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects J Clin Pharmacol 1981 21 152-156 6165742
4. Palangio M Northfelt DW Portenoy RK Brookoff D Doyle RT Jr. Dornseif BE Damask MC Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain J Pain Symptom Manage 2002 23 355-368 10.1016/S0885-3924(02)00390-1 12007754
5. Drover DR Angst MS Valle M Ramaswamy B Naidu S Stanski DR Verotta D Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers Anesthesiology 2002 97 827-836 10.1097/ 00000542-200210000-00013 12357147
6. Summary of Product Characteristics for JURNISTA ALZA Corporation, Mountain View, CA.
7. Gupta S Xu E Sathyan G Pharmacokinetic investigation of dose proportionality across the OROS hydromorphone dose range IASP Press 2005 631
8. Eckenhoff B Theeuwes F Urquhart J Osmotically activated dosage forms for rate-controlled drug delivery Pharm Technol 1981 5 35
9. Sathyan G Weiting H Gupta SK Lack of effect of food on the pharmacokinetics of an extended-release oxybutynin formulation J Clin Pharmacol 2001 41 187-192 10.1177/00912700122010014 11210400
10. Gutstein HB Akil H Opioid Analgesics Goodman & Gilman's The Pharmacological Basis of Therapeutics New York, McGraw-Hill Hardman JG, Limbird LE and Gilman AG 10th 2001 23 569 619
11. Bashaw ED Kaiko RF Grandy RP Reder RF Goldenheim PD Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade Int J Clin Pharmacol Ther 1995 33 524-529 8520812
12. FDA CDER Guidelines for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies 2002 http://www.fda.gov/cder/guidance/index.htm
13. Durnin C Hind ID Channon E Yates DB Cross M Effect of food on the pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) Proc West Pharmacol Soc 2001 44 75-76 11794001
14. Wilson CG Washington N Greaves JL Kamali F Rees JA Sempik AK Lampard JF Bimodal release of ibuprofen in a sustained-release formulation: A scintigraphic and pharmacokinetic open study in healthy volunteers under different conditions of food intake Int J Pharm 1989 50 155-161 10.1016/ 0378-5173(89)90140-3
15. Palladone™ Label 2004 http://www.fda.gov/cder/foi/label/2004/ 021044lbl.pdf